nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Mitomycin—urinary bladder cancer	0.28	0.379	CbGbCtD
Linagliptin—CYP3A4—Thiotepa—urinary bladder cancer	0.127	0.172	CbGbCtD
Linagliptin—ABCB1—Gemcitabine—urinary bladder cancer	0.0805	0.109	CbGbCtD
Linagliptin—ABCB1—Cisplatin—urinary bladder cancer	0.0585	0.0792	CbGbCtD
Linagliptin—ABCB1—Etoposide—urinary bladder cancer	0.0575	0.0779	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—urinary bladder cancer	0.0392	0.0531	CbGbCtD
Linagliptin—ABCB1—Methotrexate—urinary bladder cancer	0.038	0.0514	CbGbCtD
Linagliptin—CYP3A4—Etoposide—urinary bladder cancer	0.0344	0.0466	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—urinary bladder cancer	0.0235	0.0318	CbGbCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—urinary bladder cancer	0.00883	0.202	CbGpPWpGaD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—urinary bladder cancer	0.00785	0.179	CbGpPWpGaD
Linagliptin—DPP4—prostate gland—urinary bladder cancer	0.00732	0.127	CbGeAlD
Linagliptin—CYP3A4—urine—urinary bladder cancer	0.00665	0.116	CbGeAlD
Linagliptin—DPP4—seminal vesicle—urinary bladder cancer	0.0062	0.108	CbGeAlD
Linagliptin—DPP4—epithelium—urinary bladder cancer	0.00538	0.0935	CbGeAlD
Linagliptin—DPP4—smooth muscle tissue—urinary bladder cancer	0.00519	0.0901	CbGeAlD
Linagliptin—DPP4—renal system—urinary bladder cancer	0.00499	0.0867	CbGeAlD
Linagliptin—Bronchial hyperreactivity—Methotrexate—urinary bladder cancer	0.00435	0.0271	CcSEcCtD
Linagliptin—Urinary tract infection—Valrubicin—urinary bladder cancer	0.00414	0.0258	CcSEcCtD
Linagliptin—DPP4—female reproductive system—urinary bladder cancer	0.004	0.0695	CbGeAlD
Linagliptin—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00388	0.0885	CbGpPWpGaD
Linagliptin—DPP4—vagina—urinary bladder cancer	0.00362	0.0628	CbGeAlD
Linagliptin—Diabetic—Methotrexate—urinary bladder cancer	0.0034	0.0212	CcSEcCtD
Linagliptin—Back pain—Valrubicin—urinary bladder cancer	0.00322	0.0201	CcSEcCtD
Linagliptin—Myalgia—Valrubicin—urinary bladder cancer	0.00283	0.0177	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.00266	0.0609	CbGpPWpGaD
Linagliptin—Skin exfoliation—Thiotepa—urinary bladder cancer	0.00252	0.0157	CcSEcCtD
Linagliptin—Infection—Carboplatin—urinary bladder cancer	0.0025	0.0156	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00247	0.0154	CcSEcCtD
Linagliptin—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00239	0.0546	CbGpPWpGaD
Linagliptin—DPP4—lymph node—urinary bladder cancer	0.00234	0.0406	CbGeAlD
Linagliptin—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00212	0.0132	CcSEcCtD
Linagliptin—Cough—Mitomycin—urinary bladder cancer	0.002	0.0125	CcSEcCtD
Linagliptin—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00197	0.0123	CcSEcCtD
Linagliptin—Diarrhoea—Valrubicin—urinary bladder cancer	0.00186	0.0116	CcSEcCtD
Linagliptin—Skin exfoliation—Etoposide—urinary bladder cancer	0.00181	0.0113	CcSEcCtD
Linagliptin—Rash—Valrubicin—urinary bladder cancer	0.00171	0.0107	CcSEcCtD
Linagliptin—Dermatitis—Valrubicin—urinary bladder cancer	0.00171	0.0107	CcSEcCtD
Linagliptin—Headache—Valrubicin—urinary bladder cancer	0.0017	0.0106	CcSEcCtD
Linagliptin—ABCB1—prostate gland—urinary bladder cancer	0.00169	0.0294	CbGeAlD
Linagliptin—CYP3A4—renal system—urinary bladder cancer	0.00163	0.0283	CbGeAlD
Linagliptin—Weight increased—Thiotepa—urinary bladder cancer	0.00151	0.0094	CcSEcCtD
Linagliptin—Infestation—Thiotepa—urinary bladder cancer	0.00148	0.00921	CcSEcCtD
Linagliptin—Infestation NOS—Thiotepa—urinary bladder cancer	0.00148	0.00921	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—urinary bladder cancer	0.00147	0.00919	CcSEcCtD
Linagliptin—ABCB1—seminal vesicle—urinary bladder cancer	0.00143	0.0248	CbGeAlD
Linagliptin—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00142	0.00883	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—urinary bladder cancer	0.00136	0.00851	CcSEcCtD
Linagliptin—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00134	0.00838	CcSEcCtD
Linagliptin—CYP3A4—female reproductive system—urinary bladder cancer	0.0013	0.0227	CbGeAlD
Linagliptin—Diarrhoea—Mitomycin—urinary bladder cancer	0.00128	0.00799	CcSEcCtD
Linagliptin—Pancreatitis—Cisplatin—urinary bladder cancer	0.00127	0.00794	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00127	0.00794	CcSEcCtD
Linagliptin—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00125	0.0285	CbGpPWpGaD
Linagliptin—ABCB1—epithelium—urinary bladder cancer	0.00124	0.0216	CbGeAlD
Linagliptin—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00122	0.00761	CcSEcCtD
Linagliptin—Infestation—Fluorouracil—urinary bladder cancer	0.00122	0.00761	CcSEcCtD
Linagliptin—Immune system disorder—Thiotepa—urinary bladder cancer	0.0012	0.00746	CcSEcCtD
Linagliptin—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00119	0.00745	CcSEcCtD
Linagliptin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00119	0.0074	CcSEcCtD
Linagliptin—Rash—Mitomycin—urinary bladder cancer	0.00118	0.00736	CcSEcCtD
Linagliptin—Dermatitis—Mitomycin—urinary bladder cancer	0.00118	0.00735	CcSEcCtD
Linagliptin—Headache—Mitomycin—urinary bladder cancer	0.00117	0.00731	CcSEcCtD
Linagliptin—Malnutrition—Thiotepa—urinary bladder cancer	0.00115	0.00719	CcSEcCtD
Linagliptin—ABCB1—renal system—urinary bladder cancer	0.00115	0.02	CbGeAlD
Linagliptin—ABCB1—urethra—urinary bladder cancer	0.00113	0.0197	CbGeAlD
Linagliptin—Back pain—Thiotepa—urinary bladder cancer	0.00112	0.00696	CcSEcCtD
Linagliptin—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0011	0.0252	CbGpPWpGaD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0011	0.0251	CbGpPWpGaD
Linagliptin—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00108	0.00676	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—urinary bladder cancer	0.00106	0.00661	CcSEcCtD
Linagliptin—Infestation—Etoposide—urinary bladder cancer	0.00106	0.00661	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00101	0.00633	CcSEcCtD
Linagliptin—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00101	0.00628	CcSEcCtD
Linagliptin—Cough—Thiotepa—urinary bladder cancer	0.00101	0.00628	CcSEcCtD
Linagliptin—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.001	0.00627	CcSEcCtD
Linagliptin—Myalgia—Thiotepa—urinary bladder cancer	0.000981	0.00612	CcSEcCtD
Linagliptin—Arthralgia—Thiotepa—urinary bladder cancer	0.000981	0.00612	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000975	0.00608	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000947	0.00591	CcSEcCtD
Linagliptin—Back pain—Gemcitabine—urinary bladder cancer	0.000938	0.00585	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000938	0.00585	CcSEcCtD
Linagliptin—Immune system disorder—Cisplatin—urinary bladder cancer	0.000938	0.00585	CcSEcCtD
Linagliptin—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000936	0.00584	CcSEcCtD
Linagliptin—Infection—Thiotepa—urinary bladder cancer	0.000935	0.00583	CcSEcCtD
Linagliptin—ABCB1—female reproductive system—urinary bladder cancer	0.000923	0.016	CbGeAlD
Linagliptin—Skin disorder—Thiotepa—urinary bladder cancer	0.000914	0.0057	CcSEcCtD
Linagliptin—Malnutrition—Cisplatin—urinary bladder cancer	0.000904	0.00564	CcSEcCtD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000895	0.0204	CbGpPWpGaD
Linagliptin—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000886	0.00553	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—urinary bladder cancer	0.000859	0.00536	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000857	0.00535	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000857	0.00535	CcSEcCtD
Linagliptin—Cough—Gemcitabine—urinary bladder cancer	0.000846	0.00528	CcSEcCtD
Linagliptin—ABCB1—vagina—urinary bladder cancer	0.000835	0.0145	CbGeAlD
Linagliptin—Myalgia—Gemcitabine—urinary bladder cancer	0.000826	0.00515	CcSEcCtD
Linagliptin—Arthralgia—Gemcitabine—urinary bladder cancer	0.000826	0.00515	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.00082	0.00512	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00082	0.00512	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000812	0.00507	CcSEcCtD
Linagliptin—Myalgia—Fluorouracil—urinary bladder cancer	0.000812	0.00507	CcSEcCtD
Linagliptin—Constipation—Thiotepa—urinary bladder cancer	0.000805	0.00502	CcSEcCtD
Linagliptin—Back pain—Etoposide—urinary bladder cancer	0.000801	0.005	CcSEcCtD
Linagliptin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000791	0.00494	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.00079	0.00493	CcSEcCtD
Linagliptin—Infection—Gemcitabine—urinary bladder cancer	0.000786	0.00491	CcSEcCtD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000786	0.018	CbGpPWpGaD
Linagliptin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000778	0.00486	CcSEcCtD
Linagliptin—Infection—Fluorouracil—urinary bladder cancer	0.000773	0.00482	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—urinary bladder cancer	0.000771	0.00481	CcSEcCtD
Linagliptin—Myalgia—Cisplatin—urinary bladder cancer	0.000769	0.0048	CcSEcCtD
Linagliptin—Skin disorder—Gemcitabine—urinary bladder cancer	0.000769	0.0048	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000764	0.00477	CcSEcCtD
Linagliptin—Urticaria—Thiotepa—urinary bladder cancer	0.000747	0.00466	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000738	0.0046	CcSEcCtD
Linagliptin—Infection—Cisplatin—urinary bladder cancer	0.000733	0.00457	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000731	0.00456	CcSEcCtD
Linagliptin—Cough—Etoposide—urinary bladder cancer	0.000723	0.00451	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000721	0.0045	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—urinary bladder cancer	0.000717	0.00447	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000713	0.00445	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000709	0.00442	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000707	0.0162	CbGpPWpGaD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.0007	0.00437	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—urinary bladder cancer	0.000698	0.00436	CcSEcCtD
Linagliptin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000693	0.00433	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000689	0.0043	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000683	0.00426	CcSEcCtD
Linagliptin—Constipation—Gemcitabine—urinary bladder cancer	0.000677	0.00422	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000676	0.00422	CcSEcCtD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000676	0.0154	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000672	0.00419	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000672	0.00419	CcSEcCtD
Linagliptin—Infection—Etoposide—urinary bladder cancer	0.000671	0.00419	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000662	0.00413	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—urinary bladder cancer	0.000656	0.0041	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—urinary bladder cancer	0.000653	0.00408	CcSEcCtD
Linagliptin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000644	0.00402	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000638	0.00398	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000637	0.00397	CcSEcCtD
Linagliptin—Infestation—Methotrexate—urinary bladder cancer	0.000635	0.00396	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—urinary bladder cancer	0.000635	0.00396	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000619	0.00386	CcSEcCtD
Linagliptin—Urticaria—Fluorouracil—urinary bladder cancer	0.000618	0.00386	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—urinary bladder cancer	0.000606	0.00378	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000604	0.00377	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—urinary bladder cancer	0.000594	0.00371	CcSEcCtD
Linagliptin—Infestation—Epirubicin—urinary bladder cancer	0.000594	0.00371	CcSEcCtD
Linagliptin—Rash—Thiotepa—urinary bladder cancer	0.000593	0.0037	CcSEcCtD
Linagliptin—Dermatitis—Thiotepa—urinary bladder cancer	0.000593	0.0037	CcSEcCtD
Linagliptin—Headache—Thiotepa—urinary bladder cancer	0.000589	0.00368	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000583	0.00364	CcSEcCtD
Linagliptin—Constipation—Etoposide—urinary bladder cancer	0.000578	0.00361	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000577	0.0036	CcSEcCtD
Linagliptin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000573	0.00358	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000573	0.00357	CcSEcCtD
Linagliptin—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000562	0.0128	CbGpPWpGaD
Linagliptin—Weight increased—Doxorubicin—urinary bladder cancer	0.000561	0.0035	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00055	0.00343	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—urinary bladder cancer	0.00055	0.00343	CcSEcCtD
Linagliptin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000543	0.00339	CcSEcCtD
Linagliptin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000541	0.00338	CcSEcCtD
Linagliptin—ABCB1—lymph node—urinary bladder cancer	0.00054	0.00938	CbGeAlD
Linagliptin—Urticaria—Etoposide—urinary bladder cancer	0.000537	0.00335	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000534	0.00333	CcSEcCtD
Linagliptin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000532	0.00332	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—urinary bladder cancer	0.000515	0.00321	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000513	0.0032	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000505	0.00315	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—CDX2—urinary bladder cancer	0.000503	0.0115	CbGpPWpGaD
Linagliptin—Rash—Gemcitabine—urinary bladder cancer	0.000499	0.00311	CcSEcCtD
Linagliptin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000499	0.00311	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000498	0.00311	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—urinary bladder cancer	0.000496	0.0031	CcSEcCtD
Linagliptin—Headache—Gemcitabine—urinary bladder cancer	0.000496	0.00309	CcSEcCtD
Linagliptin—Rash—Fluorouracil—urinary bladder cancer	0.000491	0.00306	CcSEcCtD
Linagliptin—Dermatitis—Fluorouracil—urinary bladder cancer	0.00049	0.00306	CcSEcCtD
Linagliptin—Headache—Fluorouracil—urinary bladder cancer	0.000487	0.00304	CcSEcCtD
Linagliptin—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000482	0.011	CbGpPWpGaD
Linagliptin—Immune system disorder—Epirubicin—urinary bladder cancer	0.000482	0.00301	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000481	0.003	CcSEcCtD
Linagliptin—Back pain—Methotrexate—urinary bladder cancer	0.00048	0.00299	CcSEcCtD
Linagliptin—Rash—Cisplatin—urinary bladder cancer	0.000465	0.0029	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—urinary bladder cancer	0.000465	0.0029	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—urinary bladder cancer	0.000464	0.0029	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—urinary bladder cancer	0.000462	0.00289	CcSEcCtD
Linagliptin—Back pain—Epirubicin—urinary bladder cancer	0.000449	0.0028	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000446	0.00278	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000445	0.00277	CcSEcCtD
Linagliptin—Cough—Methotrexate—urinary bladder cancer	0.000433	0.0027	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000429	0.00268	CcSEcCtD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000429	0.0098	CbGpPWpGaD
Linagliptin—Rash—Etoposide—urinary bladder cancer	0.000426	0.00266	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—urinary bladder cancer	0.000426	0.00266	CcSEcCtD
Linagliptin—Headache—Etoposide—urinary bladder cancer	0.000423	0.00264	CcSEcCtD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000423	0.00967	CbGpPWpGaD
Linagliptin—Arthralgia—Methotrexate—urinary bladder cancer	0.000422	0.00264	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—urinary bladder cancer	0.000422	0.00264	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000419	0.00262	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—urinary bladder cancer	0.000415	0.00259	CcSEcCtD
Linagliptin—Cough—Epirubicin—urinary bladder cancer	0.000405	0.00253	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000405	0.00253	CcSEcCtD
Linagliptin—Infection—Methotrexate—urinary bladder cancer	0.000402	0.00251	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—urinary bladder cancer	0.000395	0.00247	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—urinary bladder cancer	0.000395	0.00247	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—urinary bladder cancer	0.000393	0.00245	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000392	0.00245	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000379	0.00236	CcSEcCtD
Linagliptin—Infection—Epirubicin—urinary bladder cancer	0.000376	0.00235	CcSEcCtD
Linagliptin—Cough—Doxorubicin—urinary bladder cancer	0.000375	0.00234	CcSEcCtD
Linagliptin—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000369	0.00844	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000369	0.0023	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—urinary bladder cancer	0.000368	0.0023	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000366	0.00228	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—urinary bladder cancer	0.000366	0.00228	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000363	0.00227	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000351	0.00219	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000349	0.00218	CcSEcCtD
Linagliptin—Infection—Doxorubicin—urinary bladder cancer	0.000348	0.00217	CcSEcCtD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000348	0.00794	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000346	0.00791	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000345	0.00215	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—urinary bladder cancer	0.00034	0.00212	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000327	0.00204	CcSEcCtD
Linagliptin—Constipation—Epirubicin—urinary bladder cancer	0.000324	0.00202	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—urinary bladder cancer	0.000322	0.00201	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000319	0.00199	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000316	0.00721	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000312	0.00712	CbGpPWpGaD
Linagliptin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000303	0.00189	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—urinary bladder cancer	0.000301	0.00188	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—urinary bladder cancer	0.0003	0.00187	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000298	0.00186	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000279	0.00174	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—urinary bladder cancer	0.000278	0.00174	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—urinary bladder cancer	0.000277	0.00173	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000259	0.00162	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000258	0.00161	CcSEcCtD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000258	0.0059	CbGpPWpGaD
Linagliptin—Rash—Methotrexate—urinary bladder cancer	0.000255	0.00159	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—urinary bladder cancer	0.000255	0.00159	CcSEcCtD
Linagliptin—Headache—Methotrexate—urinary bladder cancer	0.000254	0.00158	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00024	0.0015	CcSEcCtD
Linagliptin—Rash—Epirubicin—urinary bladder cancer	0.000239	0.00149	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—urinary bladder cancer	0.000239	0.00149	CcSEcCtD
Linagliptin—Headache—Epirubicin—urinary bladder cancer	0.000237	0.00148	CcSEcCtD
Linagliptin—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000237	0.00541	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000233	0.00533	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000224	0.00512	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000224	0.00512	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000221	0.00505	CbGpPWpGaD
Linagliptin—Rash—Doxorubicin—urinary bladder cancer	0.000221	0.00138	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000221	0.00138	CcSEcCtD
Linagliptin—Headache—Doxorubicin—urinary bladder cancer	0.00022	0.00137	CcSEcCtD
Linagliptin—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000205	0.00469	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000202	0.00462	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000192	0.00439	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000187	0.00427	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000185	0.00422	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000182	0.00416	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000165	0.00376	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000159	0.00364	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000147	0.00335	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000146	0.00333	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000146	0.00333	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—IGF1—urinary bladder cancer	0.000133	0.00305	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000133	0.00304	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000123	0.00281	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000121	0.00277	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000117	0.00268	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.00011	0.00251	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000107	0.00245	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.0001	0.00229	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	9.94e-05	0.00227	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.82e-05	0.00224	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.61e-05	0.0022	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	9.59e-05	0.00219	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.53e-05	0.00218	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.33e-05	0.00213	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.16e-05	0.00209	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.12e-05	0.00186	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.83e-05	0.00179	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.18e-05	0.00164	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.15e-05	0.00163	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.12e-05	0.00163	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.99e-05	0.0016	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.6e-05	0.00151	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.57e-05	0.0015	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.51e-05	0.00149	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.24e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.22e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.22e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.16e-05	0.00141	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.07e-05	0.00139	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.99e-05	0.00137	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.69e-05	0.0013	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.29e-05	0.00121	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.22e-05	0.00119	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.13e-05	0.00117	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.11e-05	0.00117	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.84e-05	0.00111	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.72e-05	0.00108	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.61e-05	0.00105	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.46e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.45e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.25e-05	0.00097	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.13e-05	0.000944	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.05e-05	0.000924	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.84e-05	0.000876	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.84e-05	0.000876	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.77e-05	0.000862	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.7e-05	0.000846	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.62e-05	0.000827	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.51e-05	0.000801	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.45e-05	0.000788	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.42e-05	0.000781	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.41e-05	0.000779	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.16e-05	0.000722	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.04e-05	0.000694	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.98e-05	0.000681	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.94e-05	0.000673	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.91e-05	0.000664	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.73e-05	0.000623	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.73e-05	0.000623	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.64e-05	0.000604	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.48e-05	0.000566	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.32e-05	0.000531	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.2e-05	0.000502	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.00048	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.83e-05	0.000419	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.81e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.7e-05	0.000389	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.68e-05	0.000385	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.68e-05	0.000385	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	0.000384	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.68e-05	0.000384	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000372	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.61e-05	0.000369	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.58e-05	0.000362	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.49e-05	0.00034	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000309	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.21e-05	0.000276	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.16e-05	0.000265	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.000258	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.00024	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	0.000237	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	0.000237	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.94e-06	0.000227	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.76e-06	0.000223	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.5e-06	0.000217	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.17e-06	0.00021	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.28e-06	0.000189	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—EP300—urinary bladder cancer	7.9e-06	0.00018	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.44e-06	0.00017	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.15e-06	0.000163	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.85e-06	0.000134	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.1e-06	0.000117	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.87e-06	0.000111	CbGpPWpGaD
